August 4, 2020
Our manuscript of the SalivaDirect paper has been submitted to medRxiv and for peer review! The paper covers methods and data for developing the SalivaDirect SARS-CoV-2 testing system, which is currently being reviewed by the FDA for Emergency Use Authorization.
The paper includes data supporting the key characteristics SalivaDirect brings to the SARS-CoV-2 testing game: stability of viral RNA in saliva at room temperature; efficient testing without extraction; multiplex RT-qPCR primers; and validation for a variety of test reagents and PCR machines. This data has also been available on CovidTrackerCT’s results page as we’ve collected it.
Congratulations to the entire team behind SalivaDirect. SalivaDirect development is led by Chantal Vogels, Doug Brackney, Anne Wyllie, and Nathan Grubaugh and was made possible by the entire Yale IMPACT COVID-19 Biorepository team.